
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
The National Rosacea Society has introduced the first consumer education booklet, "Understanding Rosacea," which incorporates the new standard diagnostic criteria for this common facial disorder.